wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q30402667-3ADC775B-66B9-4913-BE5F-EF4713127C37
Q30402667-3ADC775B-66B9-4913-BE5F-EF4713127C37
BestRank
Statement
http://www.wikidata.org/entity/statement/Q30402667-3ADC775B-66B9-4913-BE5F-EF4713127C37
Proteomics and biomarkers in clinical trials for drug development
P2860
Q30402667-3ADC775B-66B9-4913-BE5F-EF4713127C37
BestRank
Statement
http://www.wikidata.org/entity/statement/Q30402667-3ADC775B-66B9-4913-BE5F-EF4713127C37
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
baa4c7ef8166de71c52161867e1316fbd1386f80
P2860
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.